Back to Search

A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

  • Protocol Number: 202211187
  • Principal Investigator: Cluster, Andrew
  • Cancer Types: Siteman Kids- Pediatrics

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with brain tumors that have returned or have been resistant to treatment.

Protocol Interventions

Biological: Personalized neoantigen DNA vaccine, Device: Papivax Biotech TDS-IM v2.0, Procedure: Peripheral blood draw